The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise, Acute Myeloid Leukemia Franchise and Breakthrough Science, we aim to deliver seven distinct new molecular entities over eight years during 2018 to 2025. Our powerful research engines include two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA.
Oversees one or more trials of medium to high complexity in design and geographic scope. Such trials could be pivotal for submission; Prepares clinical section of regulatory documents; Oversees management and performance of CRO; Participates in creation of developmental and regulatory strategy; Drafts protocol profiles and sections of key submission documents; Point of contact for interactions with regulatory-agency clinical reviewing divisions on clinical matters; Represents Clinical Development in Project Teams, possibly as Global Clinical Lead.
Study Strategy: Clinical study leader (CSL) or major scientific/medical contributor; For large or complex Phase 2 studies: Provides the strategic direction to BD&O for EDC, edit checks, data quality listings, SAP, DM plan, Reviews patient population and protocol compliance for consistency with study strategy, Develops biomarker strategy in collaboration with TMCP, Collaborates with external KOLs to refine study plans; Prepares and participate in regulatory agency meetings, if applicable
Study planning and execution: As CSL for Phase 2 studies: Provides input on major milestones of trial, clinical trial plan and contingency planning, Analyzes, updates management on potential risks to study deliverables, Provides input on ICF creation, Oversees recruitment, retention; establishes and implement contingency plans for shortfalls, Consults & recruits members for DSMB and/or adjudication committee setup; Interacts with KOLs and PIs to plan study and monitor completion
Study outputs: For Phase 2 studies: Drafts responses to IRBs and HA, Collaborates with TMCP to ensure appropriate biomarker, PK / PD measurements, Reviews emerging clinical data regularly, Leads dose-escalation meetings, Performs quality assessment with delivery lead e.g. review TLG before DBL, and quality check of data, Works with BD&O to ensure SAP updates; Responsible for valid clinical interpretation of study results as Clinical Study Leader, medical monitor or regional clinical/Translational Medicine and Clinical Pharmacology representative
External collaboration: Develops and leads external advisory panels to advise on Phase 2 study strategy, design, and conduct; Interacts with KOLs for indication specific advice; Leads broad collaboration with KOLs or major institution, e.g. NCI.
Scientific, Program related: Integrated Study Team (IST) representative: Creates early development plan and contributes to overall development Strategy; Develops program biomarker strategy; Achieves endorsement for plan by function and team; Interprets and react accordingly to new preclinical/clinical data(e.g.; Go/No Go decisions, reprioritization, etc.); Operational Project Team (OPT) leader; Responsible before the IST for the creation and execution of development strategy for a program
People Management: Direct reports management - Hire and retain high quality (Team) members; Ensure team members have updated development plans and provide them with necessary means to achieve their personal development goals; Review annual goals with team members; Prepare annual performance reviews for direct reports and provide them with feedback
Additional non-study related activities: Initiates contact w/KOL and prepare material for KOL interactions on a program based need; Peripheral involvement in Business Development activities for late stage compounds Involvement with in-licensing and acquisitions on individual due diligence activities; Contributor to portfolio decisions
PharmD, PhD or equivalent; Postgraduate training in TA or related specialty. MD acceptable. Highly desirable
3 Years relevant clinical experience
Job Title Director Oncology R&D
City Basking Ridge
Functional Area Global Oncology R&D
State New Jersey Associated topics: ancmg, aoa, breast, cancer, hematology, palliative, physician md, physician md do, radiation, thedacare